

Taking place on 24 June, 2024, this ERS Vision Live panel discussion will discuss ‘Biologics in airways disease – choosing the right treatment for your patient’.
The expert panellists will discuss key areas, including:
This event is free to access but registration is required.
A trainee doctor working in London who will soon commence a competitive academic clinical post in Respiratory Medicine at Imperial College London. He has a research interest in airways disease, particularly in COPD clinical research. Sachin is also an active Early Career Member of ERS Assembly 5 and is interested in medical education, having designed and delivered multiple international respiratory teaching programmes.
Associate Professor of Medicine and Consultant Respiratory Physician at Karolinska University Hospital. He is the head of ERS Assembly 5. Apostolos meets patients with severe asthma and is the clinical lead for them at Karolinska University Hospital. He has a research interest in severe asthma, and he leads a translational research group on this at Karolinska Institutet.
Celeste is a professor of severe asthma in the Department of Respiratory Medicine at Bispebjerg Hospital, Copenhagen, Denmark, where she heads the Respiratory Research Unit and leads the Severe Asthma Clinic. Her research focuses on solving key clinical issues in difficult-to-treat asthma, understanding disease mechanisms, and personalising asthma management. Her research has covered a number of topics within asthma phenotypes, airway pathophysiology, and airway immunology mechanisms. Celeste established and chairs the Danish Severe Asthma Registry (DSAR), the ERS clinical research consortium on severe asthma – SHARP, and the European 3TR-ABC study on the effects of biologics in severe asthma.
Francesca is a physician scientist and tenured Lester and Sue Smith professor of medicine at Baylor College of Medicine, Houston, Texas, leading the COPD translational research group. Her research focuses on chronic airway diseases, lung immunology, and pathology, particularly understanding the genetic, genomic, and developmental factors behind chronic airflow limitation. She has received numerous prestigious awards, including the COPD Gold Medal from the European Respiratory Society and the Parker B. Francis Award from the American Thoracic Society. Francesca serves as section editor for the European Respiratory Journal and is a standing member of several study sections, including those for the NIH and the American Lung Association.
Ian is Professor of Respiratory Medicine at the University of Oxford and Honorary Consultant Physician at the Oxford University Hospitals. He has a research interest in the clinical aspects of inflammatory airway diseases and has pioneered the use of non-invasive measures of airway inflammation in the assessment of these conditions. He has identified a number of clinically important phenotypes of inflammatory airway disease, has discovered clinically important biomarkers, and has played a lead role in the clinical development of three of the most promising new treatments for severe airway disease. He received the 2016 European Respiratory Society (ERS) Gold Medal for his research and gave the Cournand Lecture at the 2004 ERS meeting. He chaired the 2017 Lancet Commission on asthma.